Ask us your question


Need help?

Staff's Bloodwise gift in memory of colleague

7th March 2017

Staff at Leek United Building Society have given a special cash boost to the UK's biggest blood cancer charity in memory of a former colleague.

Tony Hubbard, the Society's former Operations Director, passed away last November following a courageous battle with leukaemia.

During his illness, members of the Head Office team decided to focus their charity fundraising throughout 2016 on Bloodwise*, an organisation dedicated to improving the lives of patients such as Tony.

Various events - including dress-down days, raffles, a staff tuck shop, a mobile fish and chip van in the staff car park and the Society's annual charity golf day raised a grand total of £6,000.

A cheque for the amount was presented to Emma Jane Jones, Bloodwise's Midlands Regional Manager at Leek United's Head Office by Chief Executive Kevin Wilson.

"We are constantly inspired by the stories of those fundraising for us and the dedication of our supporters and we are truely grateful to every single member of Leek United's team for their achievement", said Emma.

"The amazing amount of money they have raised in memory of their much-loved colleague Tony will be invested in our life-saving research here in the Midlands, to help us in our mission to stop people from dying of blood cancer and make patients' lives better."

Leek United Chief Executive Kevin Wilson added: "Tony is greatly missed; the superb amount donated in his memory is a tribute to all staff involved, and we intend to continue fundraising for this very worthy cause throughout 2017.


* About Bloodwise:

Formed ub 1960, changed its name from Leukaemia & Lymphoma Research in September 2015.  Its life-saving work is focused on stopping people from dying of blood cancer, improving the quality of life for patients and their families and, where possible, stopping people getting blood cancer in the first place.

The charity's research is targeted at understanding more about blood cancer, finding causes, improving diagnosis and treatments, and running groundbreaking clinical trials for patients.

For more information visit:

Back to news